A retrospective analysis of a French registry including patients with cancer treated with immune checkpoint inhibitors revealed six cases of rheumatoid arthritis (RA) and four cases of polymyalgia rheumatica (PMR), which developed at a median of 1 month after exposure. Three patients who developed RA required DMARD therapy; the other three cases were treated with corticosteroids or NSAIDs. All four patients with PMR responded to corticosteroids.
References
Belkhir, R. et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211216 (2017)
Rights and permissions
About this article
Cite this article
Ummarino, D. Rheumatic disease after immune checkpoint inhibitor therapy. Nat Rev Rheumatol 13, 450 (2017). https://doi.org/10.1038/nrrheum.2017.113
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.113